Ming-Chung Wang

1.5k total citations
9 papers, 521 citations indexed

About

Ming-Chung Wang is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ming-Chung Wang has authored 9 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Ming-Chung Wang's work include Multiple Myeloma Research and Treatments (2 papers), Hepatitis B Virus Studies (2 papers) and Hepatitis C virus research (2 papers). Ming-Chung Wang is often cited by papers focused on Multiple Myeloma Research and Treatments (2 papers), Hepatitis B Virus Studies (2 papers) and Hepatitis C virus research (2 papers). Ming-Chung Wang collaborates with scholars based in Taiwan and United States. Ming-Chung Wang's co-authors include Sheng-Fung Lin, Pei‐Jer Chen, Hwei‐Fang Tien, Tsang-Wu Liu, Ann‐Lii Cheng, Chiun Hsu, Hui-Hua Hsiao, Chang-Fang Chiu, Johnson Lin and Wen-Li Hwang and has published in prestigious journals such as Blood, Hepatology and Scientific Reports.

In The Last Decade

Ming-Chung Wang

7 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ming-Chung Wang Taiwan	6	418	390	67	48	39	9	521
Jacques Carles France	9	130 0.3×	156 0.4×	87 1.3×	39 0.8×	57 1.5×	17	386
Yanette Suárez Spain	5	223 0.5×	357 0.9×	61 0.9×	8 0.2×	41 1.1×	8	419
Shijun Chen China	11	165 0.4×	111 0.3×	40 0.6×	35 0.7×	141 3.6×	20	400
Aldo Airoldi Italy	8	293 0.7×	441 1.1×	37 0.6×	9 0.2×	30 0.8×	14	513
Minas P. Economides United States	11	150 0.4×	148 0.4×	102 1.5×	22 0.5×	47 1.2×	27	344
Cindy K. Cheung Hong Kong	9	332 0.8×	377 1.0×	30 0.4×	18 0.4×	64 1.6×	13	509
Yuka Miyasaka Japan	10	134 0.3×	191 0.5×	30 0.4×	14 0.3×	80 2.1×	14	353
Tung Ching Chan United States	4	440 1.1×	439 1.1×	105 1.6×	35 0.7×	15 0.4×	6	553
T. Suedhoff Germany	8	195 0.5×	140 0.4×	229 3.4×	8 0.2×	38 1.0×	14	464
Hideaki Miura Japan	9	147 0.4×	231 0.6×	47 0.7×	9 0.2×	97 2.5×	22	395

Countries citing papers authored by Ming-Chung Wang

Since Specialization

Citations

This map shows the geographic impact of Ming-Chung Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming-Chung Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming-Chung Wang more than expected).

Fields of papers citing papers by Ming-Chung Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming-Chung Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming-Chung Wang. The network helps show where Ming-Chung Wang may publish in the future.

Co-authorship network of co-authors of Ming-Chung Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ming-Chung Wang. A scholar is included among the top collaborators of Ming-Chung Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming-Chung Wang. Ming-Chung Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Liao, Chun‐Kai, Chia-Jen Liu, Tran‐Der Tan, et al.. (2024). Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study. Blood. 144(Supplement 1). 5137–5137.

2.

Ma, Ming‐Chun, et al.. (2023). Real-world Evidence of Daratumumab-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Journal of Cancer Research and Practice. 10(1). 19–23.

3.

Tsai, Hui‐Jen, Shih Sheng Jiang, Wen-Chun Hung, et al.. (2017). A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Scientific Reports. 7(1). 11253–11253. 61 indexed citations

4.

Chou, Wen‐Chien, et al.. (2016). Characteristics of Taiwanese patients of PNH in the international PNH registry. Thrombosis Journal. 14(S1). 39–39. 6 indexed citations

5.

Huang, Shang‐Yi, Yuan-Bin Yu, Su‐Peng Yeh, et al.. (2016). A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. Journal of the Formosan Medical Association. 116(9). 705–710. 2 indexed citations

6.

Chiou, Tzeon-Jye, et al.. (2015). Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. Translational research. 166(6). 750–761.e4. 7 indexed citations

7.

Hsu, Chiun, Hsiao‐Hui Tsou, Ming-Chung Wang, et al.. (2013). Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 59(6). 2092–2100. 207 indexed citations

8.

Shih, Lee‐Yung, Ching-Yuan Kuo, Tsai‐Yun Chen, et al.. (2012). Emerging kinetics of BCR–ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Leukemia Research. 37(1). 43–49. 8 indexed citations

9.

Hsu, Chiun, Chao A. Hsiung, Ih‐Jen Su, et al.. (2008). A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology. 47(3). 844–853. 230 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact